FCM
NBIX icon

Farallon Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Farallon Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-72,398
Closed -$9.54M – 185
2023
Q4 		$9.54M Sell
72,398
-375,602
-84% -$43.2M 0.04% 82
2023
Q3 		$50.4M Buy
+448,000
New +$47.2M 0.24% 59

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Farallon Capital Management's NBIX Position: Q1 2024 in Review

Farallon Capital Management sold out of Neurocrine Biosciences (NBIX) in Q1 2024, closing a stake of 72,398 shares — an estimated $9.54M sold.

Farallon Capital Management first reported a position in NBIX in Q3 2023 and held it in 2 quarters. The position peaked at $50.4M in Q3 2023. 589 funds tracked by Wall St. Rank hold NBIX as of Q1 2024.

  • Farallon Capital Management reported no remaining Neurocrine Biosciences position as of Q1 2024 after selling out during the quarter.
  • Farallon Capital Management sold 72,398 Neurocrine Biosciences shares in Q1 2024, an estimated $9.54M.
  • Farallon Capital Management first reported a position in Neurocrine Biosciences in Q3 2023 and held it in 2 quarters.
  • Farallon Capital Management's Neurocrine Biosciences position peaked at $50.4M in Q3 2023.
  • 589 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2024.

Based on Farallon Capital Management's 13F filing for Q1 2024, filed 15 May 2024.